SCHEMBL6463226

SCHEMBL6463226

Cc1cc(C(O)CO)nc2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.51
BACE1 P56817 1/20 0.49
ALDH1A1 P00352 3/20 0.45
NPFFR1 Q9GZQ6 1/20 0.45
NPFFR2 Q9Y5X5 1/20 0.45
PRNP P04156 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
KDM4E B2RXH2 5/20 0.44
HPGD P15428 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MAPT P10636 3/20 0.43
TP53 P04637 1/20 0.43
L3MBTL1 Q9Y468 4/20 0.43
POLB P06746 1/20 0.43
RAB9A P51151 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
GAA P10253 3/20 0.42
ACHE P22303 1/20 0.41
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30196588 0.85 CYP1A2 (0.56) CYP1A2BACE1ALDH1A1NPFFR1NPFFR2
SCHEMBL2538873 0.85 CYP1A2 (0.56) CYP1A2BACE1ALDH1A1NPFFR1NPFFR2
SCHEMBL2600753 0.78 CYP1A2 (0.60) CYP1A2BACE1ALDH1A1NPFFR1NPFFR2
SCHEMBL17673275 0.76 CYP1A2 (0.58) CYP1A2BACE1ALDH1A1NPFFR1NPFFR2
SCHEMBL25523507 0.75 CYP1A2 (0.53) CYP1A2BACE1ALDH1A1NPFFR1NPFFR2
SCHEMBL21848468 0.75 BACE1 (0.58) CYP1A2BACE1ALDH1A1NPFFR1NPFFR2
SCHEMBL8125169 0.74 CYP1A2 (0.51) CYP1A2BACE1ALDH1A1NPFFR1NPFFR2
SCHEMBL18463865 0.73 CYP1A2 (0.55) CYP1A2BACE1ALDH1A1NPFFR1NPFFR2
SCHEMBL21834839 0.73 CYP1A2 (0.50) CYP1A2BACE1ALDH1A1NPFFR1NPFFR2
SCHEMBL526457 0.73 CYP1A2 (0.58) CYP1A2BACE1ALDH1A1NPFFR1NPFFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO disclosed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 CYP1A2 304/4885BACE1 228/4885ALDH1A1 2036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.